Dechra Pharmaceuticals PLC Price Prediction
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Oversold Vs Overbought
64
Oversold | Overbought |
Using Dechra Pharmaceuticals hype-based prediction, you can estimate the value of Dechra Pharmaceuticals PLC from the perspective of Dechra Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Dechra Pharmaceuticals to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Dechra because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Dechra Pharmaceuticals after-hype prediction price | USD 93.78 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Dechra |
Dechra Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Dechra Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Dechra Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Dechra Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Dechra Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Dechra Pharmaceuticals' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Dechra Pharmaceuticals' historical news coverage. Dechra Pharmaceuticals' after-hype downside and upside margins for the prediction period are 93.78 and 93.78, respectively. We have considered Dechra Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Dechra Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Dechra Pharmaceuticals is based on 3 months time horizon.
Dechra Pharmaceuticals Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Dechra Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dechra Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Dechra Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 0 Events / Month | 10 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
93.78 | 93.78 | 0.00 |
|
Dechra Pharmaceuticals Hype Timeline
Dechra Pharmaceuticals is currently traded for 93.78. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Dechra is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Dechra Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 93.78. The book value of the company was currently reported as 12.3. The company last dividend was issued on the 27th of October 2022. Assuming the 90 days horizon the next forecasted press release will be in a few days. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.Dechra Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Dechra Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Dechra Pharmaceuticals' future price movements. Getting to know how Dechra Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Dechra Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PFE | Pfizer Inc | 0.26 | 8 per month | 0.00 | (0.18) | 2.17 | (2.45) | 8.17 | |
| SNY | Sanofi ADR | 0.34 | 8 per month | 0.00 | (0.28) | 1.37 | (1.85) | 7.81 | |
| BMY | Bristol Myers Squibb | 0.07 | 8 per month | 1.18 | 0.12 | 2.23 | (2.07) | 14.39 | |
| AZN | AstraZeneca PLC ADR | 0.37 | 7 per month | 0.00 | (0.34) | 1.28 | (3.18) | 8.50 | |
| GILD | Gilead Sciences | 0.29 | 8 per month | 1.01 | 0.12 | 2.17 | (1.82) | 10.80 | |
| NVS | Novartis AG ADR | 0.29 | 8 per month | 0.00 | (0.33) | 1.12 | (1.98) | 6.05 | |
| MRK | Merck Company | (1.15) | 7 per month | 0.00 | (0.25) | 2.00 | (2.13) | 4.89 | |
| GSK | GlaxoSmithKline PLC ADR | 0.18 | 11 per month | 0.00 | (0.33) | 1.27 | (2.56) | 8.87 | |
| AMGN | Amgen Inc | 6.77 | 8 per month | 0.00 | (0.20) | 1.67 | (4.16) | 9.43 | |
| ABBV | AbbVie Inc | 3.14 | 8 per month | 0.00 | (0.1) | 2.30 | (2.11) | 18.93 | |
| JNJ | Johnson Johnson | (0.73) | 7 per month | 0.00 | (0.23) | 1.40 | (1.42) | 3.25 |
Dechra Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Dechra price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Dechra using various technical indicators. When you analyze Dechra charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Dechra Pharmaceuticals Predictive Indicators
The successful prediction of Dechra Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Dechra Pharmaceuticals PLC, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Dechra Pharmaceuticals based on analysis of Dechra Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Dechra Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Dechra Pharmaceuticals's related companies.
Story Coverage note for Dechra Pharmaceuticals
The number of cover stories for Dechra Pharmaceuticals depends on current market conditions and Dechra Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Dechra Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Dechra Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Dechra Pharmaceuticals Short Properties
Dechra Pharmaceuticals' future price predictability will typically decrease when Dechra Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Dechra Pharmaceuticals PLC often depends not only on the future outlook of the potential Dechra Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dechra Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 108.4 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |